1st Quarter - Report

EDWARDS LIFESCIENCES, LLC for EDWARDS LIFESCIENCES LLC

Firm
Client
Income
—
Expenses
$340,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

CMS Coverage Policies CMS Payment Policies 21st Century Cures and other Device Innovation Initiatives

LobbyistCovered position, as disclosed
ELIZABETH RAYE KEGLER —
BARRY ROBERT LIDEN —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Taxation/Internal Revenue Code TAX

Implementation of PL-111-148, Medical Device Tax Foreign Source Income Tax Deferral Taxation of Offshore Income Tax Reform Federal Corporate Tax Rate Repatriation Transfer Pricing R&D Tax Credit Domestic Manufacturing Credit H.R 160, Protect Medical Innovation Act of 2015 S. 149 Medical Device Access & Innovation Protection Act Patent Box

LobbyistCovered position, as disclosed
ELIZABETH RAYE KEGLER —
BARRY ROBERT LIDEN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Bills named: S. 149 (114th), H.R. 160 (114th)

Health Issues HCR

Implementation of PL-111-148, Patient Protection and Affordable Care Act Implementation of PL-112-144, Food and Drug Administration Safety and Innovation Act Enhanced Surgical Recovery Protocols 21st Century Cures and other Device Innovation Initiatives

LobbyistCovered position, as disclosed
ELIZABETH RAYE KEGLER —
BARRY ROBERT LIDEN —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.